Investment House LLC Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)


Share on StockTwits

Investment House LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 1.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 115,013 shares of the company’s stock after buying an additional 1,287 shares during the quarter. Johnson & Johnson makes up 1.3% of Investment House LLC’s portfolio, making the stock its 19th biggest position. Investment House LLC’s holdings in Johnson & Johnson were worth $18,101,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Redpoint Investment Management Pty Ltd lifted its position in Johnson & Johnson by 6.0% in the 4th quarter. Redpoint Investment Management Pty Ltd now owns 67,919 shares of the company’s stock valued at $10,689,000 after acquiring an additional 3,815 shares in the last quarter. Pinnacle Financial Partners Inc. lifted its position in Johnson & Johnson by 0.5% in the 4th quarter. Pinnacle Financial Partners Inc. now owns 106,221 shares of the company’s stock valued at $16,691,000 after acquiring an additional 480 shares in the last quarter. McGuire Investment Group LLC lifted its position in Johnson & Johnson by 43.2% in the 4th quarter. McGuire Investment Group LLC now owns 67,100 shares of the company’s stock valued at $10,560,000 after acquiring an additional 20,250 shares in the last quarter. Ellenbecker Investment Group lifted its position in Johnson & Johnson by 6.9% in the 4th quarter. Ellenbecker Investment Group now owns 4,298 shares of the company’s stock valued at $676,000 after acquiring an additional 278 shares in the last quarter. Finally, OneAscent Financial Services LLC bought a new position in Johnson & Johnson in the 4th quarter valued at approximately $218,000. Institutional investors own 61.26% of the company’s stock.

JNJ opened at $157.89 on Thursday. The firm has a market cap of $415.65 billion, a P/E ratio of 24.83, a P/E/G ratio of 3.30 and a beta of 0.68. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $161.32. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. The stock has a 50-day moving average of $152.86 and a 200 day moving average of $148.31.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. During the same quarter last year, the firm earned $2.12 earnings per share. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 9th. Shareholders of record on Tuesday, February 23rd will be issued a $1.01 dividend. The ex-dividend date is Monday, February 22nd. This represents a $4.04 dividend on an annualized basis and a yield of 2.56%. Johnson & Johnson’s payout ratio is 46.54%.

In other news, COO Michael E. Sneed sold 54,662 shares of the firm’s stock in a transaction that occurred on Wednesday, December 9th. The shares were sold at an average price of $152.93, for a total transaction of $8,359,459.66. Following the completion of the sale, the chief operating officer now owns 110,741 shares in the company, valued at approximately $16,935,621.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is currently owned by corporate insiders.

Several research firms recently issued reports on JNJ. Credit Suisse Group upped their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research report on Wednesday, October 14th. Raymond James reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Friday, November 20th. Cantor Fitzgerald increased their price target on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. BidaskClub raised Johnson & Johnson from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 6th. Finally, Morgan Stanley increased their price target on Johnson & Johnson from $170.00 to $178.00 and gave the company an “overweight” rating in a report on Tuesday, December 15th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $165.50.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also: Strangles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.